Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Myeloid 2

Conditions

Polycythemia Vera 2Thrombocythemia, Essential 1Primary Myelofibrosis 1

Interventions

fludarabine 30Specimen Handling 28Cyclophosphamide 27Azacitidine 23venetoclax 22fludarabine phosphate 22Biopsy 22ruxolitinib 18Whole-Body Irradiation 17Cytarabine 17Mycophenolic Acid 16Busulfan 16asciminib 15Tacrolimus 15Melphalan 14Injections 12Decitabine 12decitabine and cedazuridine drug combination 11X-Rays 11Magnetic Resonance Spectroscopy 11Stem Cell Transplantation 10Granulocyte Colony-Stimulating Factor 10Sirolimus 9Peripheral Blood Stem Cell Transplantation 9Cyclosporine 9Thiotepa 8Filgrastim 8nilotinib 7Imatinib Mesylate 7Phantoms, Imaging 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
bomedemstat × Myeloid × 90 days × Clear all
NCT05558696 2026-05-07

IMG-7289-CTP-203

Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)

Phase 2 Completed
20 enrolled 19 charts
Myeloid

Polycythemia Vera

NCT06351631 2026-04-02

MK-3543-017

Merck Sharp & Dohme LLC

Phase 3 Recruiting
400 enrolled
Myeloid

Polycythemia Vera, Thrombocythemia, Essential, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡